Breast Cancer
Carrick Therapeutics Limited focuses on clinical research in metastatic and locally advanced breast cancer, with particular interest in hormone receptor-positive and HER2-negative disease.
- Hormone receptor-positive breast cancer
- HER2-negative breast cancer
- Metastatic breast cancer
- Locally advanced breast cancer
The sponsor’s activity is centered on treatment settings where endocrine-driven disease control remains a key therapeutic need.
Endocrine-Targeted Therapy
The funded studies examine combinations involving samuraciclib with established endocrine therapies in HR-positive breast cancer.
- Elacestrant
- Fulvestrant
- Endocrine resistance
- Hormone receptor signaling
These interests align with clinical settings where modulation of hormone-driven pathways is central to disease management.
Cell Cycle and CDK Pathways
Research activity also reflects interest in cyclin-dependent kinase biology, particularly mechanisms relevant to cell cycle regulation in breast cancer.
- CDK inhibition
- Cell proliferation control
- Tumor growth suppression
- Combination oncology therapy
This area supports investigation of targeted approaches for disease that persists despite standard hormonal treatment.
Oncology Clinical Development
The sponsor maintains an active oncology development portfolio across multiple countries and collaborating sites, with ongoing work in breast cancer therapeutics.
- Clinical oncology
- Advanced solid tumors
- Therapeutic combinations
- Progression-free survival
Its research footprint is concentrated on treatment options for patients with advanced hormone-responsive disease.
